Chiome Bioscience Inc
TSE:4583
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
81
180
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Chiome Bioscience Inc
Total Liabilities & Equity
Chiome Bioscience Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Chiome Bioscience Inc
TSE:4583
|
Total Liabilities & Equity
¥1.7B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-9%
|
|
|
CMIC Holdings Co Ltd
TSE:2309
|
Total Liabilities & Equity
¥67.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
5%
|
|
|
Precision System Science Co Ltd
TSE:7707
|
Total Liabilities & Equity
¥6.4B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
|
Medinet Co Ltd
TSE:2370
|
Total Liabilities & Equity
¥5.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-6%
|
|
|
CellSource Co Ltd
TSE:4880
|
Total Liabilities & Equity
¥6.9B
|
CAGR 3-Years
43%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
WDB coco Co Ltd
TSE:7079
|
Total Liabilities & Equity
¥4.7B
|
CAGR 3-Years
30%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
Chiome Bioscience Inc
Glance View
Chiome Bioscience, Inc. engages in the development and sale of antibody drugs through the Autonomous Diversifying Library (ADLib) system. The company is headquartered in Shibuya-Ku, Tokyo-To and currently employs 37 full-time employees. The company went IPO on 2011-12-20. The firm operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.
See Also
What is Chiome Bioscience Inc's Total Liabilities & Equity?
Total Liabilities & Equity
1.7B
JPY
Based on the financial report for Sep 30, 2024, Chiome Bioscience Inc's Total Liabilities & Equity amounts to 1.7B JPY.
What is Chiome Bioscience Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-9%
Over the last year, the Total Liabilities & Equity growth was -3%. The average annual Total Liabilities & Equity growth rates for Chiome Bioscience Inc have been -17% over the past three years , -11% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet
